Advertisement
DMAC Notícias Sobre o Forex
DiaMedica Appoints Lorianne Masuoka As Chief Medical Officer
Biopharmaceutical company DiaMedica Therapeutics Inc. (DMAC) announced Monday the appointment of Lorianne Masuoka as Chief Medical Officer. Masuoka is a board-certified neurologist with more than 25 years of experience in managing clinical programs from early stage to drug approvals and strategic alliances.
RTTNews
|
584 dias atrás
DiaMedica Therapeutics Says FDA Lifts Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
Biopharmaceutical company DiaMedica Therapeutics Inc. (DMAC) announced Wednesday that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS).
RTTNews
|
799 dias atrás
